Biocryst Pharmaceuticals expects to complete Phase I testing of its Peramivir antiviral by next March, and while the company expects to complete Phases II and III tests, the government may intervene to contribute to U.S. stockpiles of drugs to combat a possible flu outbreak. Pre-clinical testing in mice showed the drug could cure the avian flu virus without side effects and NIH is providing funding for the trials. The government has not offered Biocryst a contract at this time, however.

Full Story:

Related Summaries